PFE
BEARISHAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Rule-based valuation (P/E + Graham).
- Insufficient data for clear positives.
- Trades above Graham Number.
Rule-based growth outlook.
- Insufficient data for clear positives.
- Revenue is contracting.
Historical performance + price trend: Shares moved +1.1% over 5Y and +24.9% over 1Y.
- Insufficient data for clear positives.
Balance sheet & liquidity (Z-Score: N/A).
- Insufficient data for clear positives.
Dividend policy fallback.
- Moderate dividend profile (Score: 40/100).
- Yield: 6.1%.
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for PFE and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
PFE
Pfizer Inc.
Primary
|
+1.1% | -17.2% | +24.9% | +8.7% | +4.8% | +4.8% |
|
GILD
Gilead Sciences, Inc.
Peer
|
+144.5% | +69.7% | +29.3% | +10.8% | -3.2% | -4.9% |
|
ISRG
Intuitive Surgical, Inc.
Peer
|
+56.7% | +55.1% | -0.6% | +1.6% | -2.6% | +1.4% |
|
ABT
Abbott Laboratories
Peer
|
-10.8% | +2.5% | -18.4% | -21.1% | -7.6% | -1.9% |
|
DHR
Danaher Corporation
Peer
|
-7.7% | -11.3% | +6.4% | -5.9% | +3.5% | -0.2% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
PFE
Pfizer Inc.
|
BEARISH | $162.54B | 21.01 | 8.9% | 12.4% | $28.57 | |
|
GILD
Gilead Sciences, Inc.
|
NEUTRAL | $164.96B | 19.6 | 40.7% | 28.9% | $132.9 | Compare |
|
ISRG
Intuitive Surgical, Inc.
|
NEUTRAL | $165.37B | 59.16 | 16.7% | 28.4% | $465.6 | Compare |
|
ABT
Abbott Laboratories
|
NEUTRAL | $176.48B | 27.3 | 13.0% | 14.7% | $101.56 | Compare |
|
DHR
Danaher Corporation
|
NEUTRAL | $138.36B | 38.94 | 7.1% | 14.7% | $195.5 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-03 | DAMICO JENNIFER B. | Officer | Stock Award | 21,719 | - |
| 2026-02-25 | BOSHOFF CHRISTOFFEL | Officer | Stock Award | 13,383 | - |
| 2026-02-25 | SAHNI PAYAL | Officer | Option Exercise | 56,888 | $1,923,952 |
| 2026-02-25 | MCDERMOTT MICHAEL | Officer | Option Exercise | 37,925 | $1,282,624 |
| 2026-02-25 | BOURLA ALBERT | Chief Executive Officer | Option Exercise | 491,626 | $16,626,791 |
| 2026-02-25 | DAMICO JENNIFER B. | Officer | Option Exercise | 17,558 | $593,812 |
| 2026-02-25 | FONSECA LIDIA PH.D. | Officer | Option Exercise | 56,888 | $1,923,952 |
| 2026-02-25 | LANKLER DOUGLAS M | Officer | Option Exercise | 122,907 | $4,156,715 |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning PFE from our newsroom.